Roche announced a major expansion of its AI infrastructure in collaboration with Nvidia to accelerate drug discovery, diagnostics and biomanufacturing workflows. The company said it will deploy thousands of GPUs across hybrid cloud and on‑premises environments to power large‑scale biological reasoning and generative models for therapeutic design. The deal builds on industry momentum toward petascale compute for life sciences; Roche’s announced deployment follows similar investments by peers and aligns with announcements at Nvidia’s GTC event that spotlighted healthcare as a major growth vector for AI infrastructure. Roche and Nvidia framed the partnership as an effort to shorten R&D timelines, improve diagnostic throughput and scale computational experiments that underpin AI‑driven molecule and biomarker discovery. The move further signals competition among large pharmas to control compute capacity and AI pipelines.